MEL inhibits the ras-related C3 botulinum toxin substrate 1 (Rac1) (Choi et al., 2014), which participates in the c-Jun N-terminal kinase (JNK) and JNK-dependent cell motility processes and causes metastasis, preventing hepatocellular carcinoma cell metastasis. Here, RAC1 is linked to hepatocellular carcinoma.